Is FDA More Conservative Than EMEA? FDA Says No; Investors Weigh In

Office of New Drugs director John Jenkins debates the perception that FDA approves fewer products than its regulatory counterparts in Europe. But some investors see troubling trends in data presented by the agency at the FDA/CMS Summit.

When it comes to the FDA approval process, Office of New Drugs director John Jenkins wants to make one thing very clear. All those external analyses that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown.

During a keynote presentation at FDC-Windhover’s FDA/CMS Summit for Biopharma Executives on December 4, Jenkins acknowledged recent criticism from analysts...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet